Business Context and Reporting Period
MEDICINOVA INC filed this Form 8-K on November 12, 2009, to disclose a Japanese report ("Kessan Tanshin") filed with the Osaka Securities Exchange on November 13, 2009 (Japanese Standard Time). The report provides updated financial results and forecasts for the quarter ended September 30, 2009, and the full fiscal year ending December 31, 2009.
Key Financial Metrics
| Metric | Value |
|---|---|
| Full Year 2009 Revenue Forecast | $0 |
| Full Year 2009 Operating Loss Forecast | $(22,400,000) |
| Full Year 2009 Net Loss Forecast | $(21,600,000) |
| Expected Basic and Diluted Loss Per Share | $(1.79) |
| Anticipated Cash Burn (Full Year) | Less than $22,000,000 |
| Weighted Average Shares Outstanding | 12,098,440 |
The filing does not provide specific revenue, profit, or cash flow figures for the quarter ended September 30, 2009, stating only that the Tanshin is substantially the same as the Form 10-Q for that period.
Material Changes Versus Prior Period
The Company revised its estimated results of operations for the full year 2009 from those previously provided in a report filed on April 1, 2009. The variance is primarily attributed to:
- Initiation of the Phase Ib clinical trial for MN-221 in patients with chronic obstructive pulmonary disease in the fourth quarter of 2009.
- Fees and expenses related to the pending acquisition of Avigen, Inc.
Guidance, Outlook, and Risks
Management forecasts a full-year cash burn of less than $22 million, which includes a $3.0 million payment to Avigen in connection with the proposed merger. The filing includes extensive forward-looking statements and risk disclosures, noting that actual results may differ materially due to:
- Uncertainties inherent in clinical trials and product development.
- Risks regarding regulatory approval and third-party performance.
- Market factors, including credit and capital market conditions affecting the investment portfolio.
- Currency exchange rate fluctuations.
Management explicitly states that independent auditors have not compiled or reviewed these forecasted results and assume no responsibility for their accuracy.
Investor Verification Checklist
- Verify the specific quarterly financial results for the period ended September 30, 2009, in the Company's Form 10-Q, as this 8-K only provides full-year forecasts.
- Confirm the status and timeline of the pending acquisition of Avigen, Inc., and the associated $3.0 million payment obligation.
- Monitor the progress and costs of the Phase Ib clinical trial for MN-221, which is a primary driver of the increased loss forecast.
- Review the Company's liquidity position and capital resources to ensure sufficiency to fund the projected cash burn of under $22 million.